Keros Therapeutics Inc (KROS)

$16.12 +0.16 (1.00%)
Market Cap 648.22M
Revenue (ttm) 3.55M
Net Income (ttm) -187.35M
EPS (ttm) N/A
PE Ratio 50.48
Forward PE 47.60
Profit Margin -5,277.47%
Debt to Equity Ratio 0.00
Volume 508,900
Avg Vol 429,690
Day's Range N/A - N/A
Shares Out 40.62M
Stochastic %K 71%
Beta 0.97
Analysts Sell
Price Target $23.33

Company Profile

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in pat...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 314 6297
Address:
1050 Waltham Street, Suite 302, Lexington, United States
Thatcher123
Thatcher123 Oct. 9 at 4:56 PM
$LMT Graphene is a "miracle" material 200X stronger than steel, lighter than aluminum and 20X more conductive than copper "Here are some uses of graphene for the Defense industry: this alone boggles the mind. Robots, Drones, bullet proof body armor, bullet proof glass, the frames of vehicles (imbedded in the steel), special coatings, microwave field around unmanned drones, engineering fibers like a nylon for a kevlar vest, ballistic protection, armored vehicles, aerospace components, concrete for blast walls, coatings on all military vehicles like tanks, lubricating oils. We haven’t even touched on the auto industry. " "We make the best Graphene in the World!" Hydrograph Clean Power HGRAF www.hydrograph.com Watch Youtube https://youtu.be/oLxQI8RCXjc HydroGraph Solved Graphene's Biggest Problem (And It's About to Pay Off Big) https://www.youtube.com/watch?v=JD6REGB8Vu4&t=17s Is Graphene the new OIL ?? https://x.com/i/status/1957095349144764583 $RTX $KROS $LILM
0 · Reply
CyberCuba
CyberCuba Oct. 6 at 2:50 PM
$KROS Looks like KROS finally breaking out through $16 with all recent dips being quickly bought. Goldman Sachs Group Inc. increased its holdings in shares of Keros Therapeutics, Inc by 38.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 740,606 shares of the company's stock after purchasing an additional 205,022 shares during the quarter. Goldman Sachs Group Inc. owned 1.82% of Keros Therapeutics worth $7,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Two Sigma Investments LP lifted its holdings in shares of Keros Therapeutics by 226.1% during the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock valued at $533,000 after purchasing an additional 23,342 shares in the last quarter.
1 · Reply
ScalperZed
ScalperZed Oct. 5 at 9:29 AM
$KROS Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
JasonCO
JasonCO Sep. 30 at 4:08 PM
$KROS wrong board
0 · Reply
JasonCO
JasonCO Sep. 30 at 4:08 PM
$KROS Dgaf
0 · Reply
buyandsold
buyandsold Sep. 30 at 2:29 PM
$KROS should I see if they have a tender offer template at my Legal Forms store and send it in to help out?
0 · Reply
TalkMarkets
TalkMarkets Sep. 29 at 10:05 PM
Bargain Hunters’ Delight: Four Stocks Trading Below Cash Per Share With Minimal Debt $GDOT $ARVN $KROS $ALMS https://talkmarkets.com/content/stocks--equities/bargain-hunters-delight-four-stocks-trading-below-cash-per-share-with-minimal-debt?post=525519
0 · Reply
JasonCO
JasonCO Sep. 25 at 9:07 PM
$KROS all dips bought
0 · Reply
buyandsold
buyandsold Sep. 22 at 5:20 AM
$KROS tender offer price will be? I think $18
1 · Reply
CyberCuba
CyberCuba Sep. 18 at 5:19 PM
$KROS please develop a crypto treasury with $375 million due investors. if so, stock price will increase tenfold!
1 · Reply
Latest News on KROS
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Sep 8, 2025, 8:00 AM EDT - 4 weeks ago

Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Aug 28, 2025, 4:01 PM EDT - 6 weeks ago

Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Aug 21, 2025, 8:30 AM EDT - 7 weeks ago

ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Aug 20, 2025, 9:48 AM EDT - 7 weeks ago

Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Aug 6, 2025, 4:15 PM EDT - 2 months ago

Keros to Exclusively Prioritize the Clinical Advancement of KER-065

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:01 PM EDT - 2 months ago

Keros Therapeutics Reports Second Quarter 2025 Financial Results

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Jul 17, 2025, 8:00 AM EDT - 3 months ago

Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Jun 9, 2025, 3:12 PM EDT - 4 months ago

ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Jun 9, 2025, 6:55 AM EDT - 4 months ago

Keros Announces Return of $375 Million in Excess Capital to Stockholders

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 4:01 PM EDT - 4 months ago

Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

May 29, 2025, 6:55 AM EDT - 4 months ago

Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

May 27, 2025, 1:45 PM EDT - 4 months ago

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros' Director Nominees

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 21, 2025, 8:00 AM EDT - 5 months ago

ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

May 12, 2025, 12:11 PM EDT - 5 months ago

ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

May 12, 2025, 8:00 AM EDT - 5 months ago

Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Keros Reinforces Commitment to Maximizing Stockholder Value

May 8, 2025, 5:31 PM EDT - 5 months ago

Keros Reinforces Commitment to Maximizing Stockholder Value

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

May 8, 2025, 2:10 PM EDT - 5 months ago

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

May 6, 2025, 4:01 PM EDT - 5 months ago

Keros Therapeutics Reports Recent First Quarter 2025 Financial Results

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Apr 10, 2025, 1:51 PM EDT - 6 months ago

Keros Therapeutics Goes Up For Sale On Heels Of Stockholder Rights Plan

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Apr 10, 2025, 12:12 PM EDT - 6 months ago

Crude Oil Falls Over 4%; Keros Therapeutics Shares Jump

Keros Therapeutics adopts 'poison pill' plan

Apr 10, 2025, 6:10 AM EDT - 6 months ago

Keros Therapeutics adopts 'poison pill' plan

Keros Therapeutics Announces Review of Strategic Alternatives

Apr 10, 2025, 6:00 AM EDT - 6 months ago

Keros Therapeutics Announces Review of Strategic Alternatives

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Mar 31, 2025, 6:00 AM EDT - 6 months ago

Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:01 PM EST - 8 months ago

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 8 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN LLY NVO REGN SRRK

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Jan 31, 2025, 10:00 AM EST - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Shareholders to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 30, 2025, 10:00 AM EST - 9 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 8:00 AM EST - 9 months ago

Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Jan 29, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Jan 28, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Jan 27, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Keros Therapeutics, Inc. (KROS) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Jan 26, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Investors to Learn More About the Investigation

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 24, 2025, 10:00 AM EST - 9 months ago

Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Jan 23, 2025, 10:00 AM EST - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Keros Therapeutics, Inc. (KROS) And Encourages Investors to Connect

Thatcher123
Thatcher123 Oct. 9 at 4:56 PM
$LMT Graphene is a "miracle" material 200X stronger than steel, lighter than aluminum and 20X more conductive than copper "Here are some uses of graphene for the Defense industry: this alone boggles the mind. Robots, Drones, bullet proof body armor, bullet proof glass, the frames of vehicles (imbedded in the steel), special coatings, microwave field around unmanned drones, engineering fibers like a nylon for a kevlar vest, ballistic protection, armored vehicles, aerospace components, concrete for blast walls, coatings on all military vehicles like tanks, lubricating oils. We haven’t even touched on the auto industry. " "We make the best Graphene in the World!" Hydrograph Clean Power HGRAF www.hydrograph.com Watch Youtube https://youtu.be/oLxQI8RCXjc HydroGraph Solved Graphene's Biggest Problem (And It's About to Pay Off Big) https://www.youtube.com/watch?v=JD6REGB8Vu4&t=17s Is Graphene the new OIL ?? https://x.com/i/status/1957095349144764583 $RTX $KROS $LILM
0 · Reply
CyberCuba
CyberCuba Oct. 6 at 2:50 PM
$KROS Looks like KROS finally breaking out through $16 with all recent dips being quickly bought. Goldman Sachs Group Inc. increased its holdings in shares of Keros Therapeutics, Inc by 38.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 740,606 shares of the company's stock after purchasing an additional 205,022 shares during the quarter. Goldman Sachs Group Inc. owned 1.82% of Keros Therapeutics worth $7,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Two Sigma Investments LP lifted its holdings in shares of Keros Therapeutics by 226.1% during the fourth quarter. Two Sigma Investments LP now owns 33,664 shares of the company's stock valued at $533,000 after purchasing an additional 23,342 shares in the last quarter.
1 · Reply
ScalperZed
ScalperZed Oct. 5 at 9:29 AM
$KROS Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
JasonCO
JasonCO Sep. 30 at 4:08 PM
$KROS wrong board
0 · Reply
JasonCO
JasonCO Sep. 30 at 4:08 PM
$KROS Dgaf
0 · Reply
buyandsold
buyandsold Sep. 30 at 2:29 PM
$KROS should I see if they have a tender offer template at my Legal Forms store and send it in to help out?
0 · Reply
TalkMarkets
TalkMarkets Sep. 29 at 10:05 PM
Bargain Hunters’ Delight: Four Stocks Trading Below Cash Per Share With Minimal Debt $GDOT $ARVN $KROS $ALMS https://talkmarkets.com/content/stocks--equities/bargain-hunters-delight-four-stocks-trading-below-cash-per-share-with-minimal-debt?post=525519
0 · Reply
JasonCO
JasonCO Sep. 25 at 9:07 PM
$KROS all dips bought
0 · Reply
buyandsold
buyandsold Sep. 22 at 5:20 AM
$KROS tender offer price will be? I think $18
1 · Reply
CyberCuba
CyberCuba Sep. 18 at 5:19 PM
$KROS please develop a crypto treasury with $375 million due investors. if so, stock price will increase tenfold!
1 · Reply
buyandsold
buyandsold Sep. 17 at 2:41 PM
$KROS is announcing a return of capital with no method or deadline a boss move?! It keeps the stock price steady while you swan around conferences chatting about a new moonshot science project.
0 · Reply
Ub3r5pAnK
Ub3r5pAnK Sep. 11 at 2:09 AM
$LMT $RTX $KROS Dont forget Neuromorphic Chips to enhance battery life.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 5:51 AM
$KROS Brilliant piece that captures KROS's situation perfectly. So if you want to update your understanding of KROS or get to know KROS better, this is essential reading. https://beyondspx.com/quote/KROS/analysis/keros-therapeutics-a-strategic-pivot-towards-focused-innovation-and-shareholder-value-nasdaq-kros
1 · Reply
Thatcher123
Thatcher123 Sep. 9 at 9:06 PM
$LMT THE NEXT GENERATION OF ADVANCED DRONES--GRAPHENE "The Drone Example: The next generation of advanced drones will likely be made with high strength graphene enhanced polymers with reduced weight, perhaps even bullet proof, they will contain superior solid state graphene enhanced batteries for longer range and vastly superior charge times. They could be topped with graphene enhanced solar panels coatings for daytime recharging. The Graphene enhanced blades will be thinner and stronger, more aerodynamic, more efficient, increasing range and probably making them fly quieter." "We make the best Graphene in the World!" Hydrograph Clean Power HGRAF www.hydrograph.com HydroGraph Solved Graphene's Biggest Problem (And It's About to Pay Off Big) https://www.youtube.com/watch?v=JD6REGB8Vu4&t=17s Graphene is the miracle material that is stronger than steel, lighter than paper and the best conductor of electricity on Earth. $RTX $KROS Hydrograph HGRAF CEO President & Board Chair Kjirstin Breure
1 · Reply
Thatcher123
Thatcher123 Sep. 7 at 6:51 PM
$LMT THE NEST GENERATION OF ADVANCED DRONES--GRAPHENE "The Drone Example: The next generation of advanced drones will likely be made high strength graphene enhanced polymers with reduced weight, perhaps even bullet proof, they will contain superior solid state graphene enhanced batteries for longer range and vastly superior charge times. They could be topped with graphene enhanced solar panels coatings for daytime recharging. The Graphene enhanced blades will be thinner and stronger, more aerodynamic, more efficient, increasing range and probably making them fly quieter." "We make the best Graphene in the World!" Hydrograph Clean Power HGRAF www.hydrograph.com Watch Youtube https://youtu.be/oLxQI8RCXjc HydroGraph Solved Graphene's Biggest Problem (And It's About to Pay Off Big) https://www.youtube.com/watch?v=JD6REGB8Vu4&t=17s Graphene is the miracle material that is stronger than steel, lighter than paper and the best conductor of electricity on Earth. $RTX $KROS HGRAF CEO President & Board Chair Kjirstin Breure
0 · Reply
JasonCO
JasonCO Sep. 5 at 6:31 PM
$KROS eat
0 · Reply
CyberCuba
CyberCuba Sep. 5 at 12:35 PM
$KROS The share price does better when the CEO is not talking at healthcare conferences.
0 · Reply
MacGruber99
MacGruber99 Sep. 4 at 6:57 PM
$KROS Company reiterated plan to return cash to investors, details forthcoming; now focused on first indication but open to second neuromuscular program using KER-065
0 · Reply
buyandsold
buyandsold Sep. 3 at 1:37 AM
$KROS the big problem with this company is that the management seem intent on incinerating shareholder cash to save their jobs
1 · Reply
buyandsold
buyandsold Sep. 2 at 2:48 PM
$KROS buyout discussions are an explanation for delayed didvidend announcement. But I think they have changed their mind and are burning legal fees on how to reverse.
1 · Reply
JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS wrong board lol
0 · Reply
JasonCO
JasonCO Aug. 26 at 1:59 PM
$KROS do it
0 · Reply